Clinical Report: Biomarkers and Cardiac Characteristics Linked to Atrial Fibrillation
Overview
This study identifies a significant association between BNP/LVEF and atrial fibrillation (AF) in a hospitalized population. The findings suggest that BNP/LVEF can serve as a useful biomarker for AF risk stratification.
Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and poses a significant public health challenge due to its association with increased morbidity and mortality. Understanding the risk factors and biomarkers associated with AF is crucial for early identification and management, particularly in hospitalized patients. This study focuses on the combined utility of B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) in predicting AF risk.
Data Highlights
Parameter
Value
Patients with AF
123 (45.6%)
Odds Ratio for BNP/LVEF
1.02 (95% CI, 1.01–1.04)
AUC for BNP/LVEF
0.84
Key Findings
Higher BNP/LVEF values are independently associated with increased AF risk.
Significant non-linear relationship observed between BNP/LVEF and AF risk.
BNP/LVEF demonstrated good discriminatory ability for AF with an AUC of 0.84.
Subgroup analyses revealed heterogeneity across sex, smoking, alcohol consumption, and coronary heart disease status.
BNP is a well-established biomarker for cardiac dysfunction and cardiovascular risk stratification.
Clinical Implications
The integration of BNP and LVEF as a composite biomarker may enhance risk stratification for atrial fibrillation in hospitalized patients. Clinicians should consider these parameters when assessing AF risk to improve patient management and outcomes.
Conclusion
BNP/LVEF is a valuable integrative marker for predicting atrial fibrillation risk, demonstrating both independent and non-linear associations. This finding underscores its potential role in clinical risk stratification.
Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.
